Giovanni Zambello

Dr. Giovanni Zambello


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
Eleonora FaccioliEleonora Faccioli
Eleonora Faccioli
GZGiovanni Zambello
Giovanni Zambello
DTDiletta Trojan
Diletta Trojan
GCGianluca Canu
Gianluca Canu
VSViola Sambataro
Viola Sambataro
FRFederico Rea
Federico Rea
Synthetic materials have traditionally been used to reconstruct the diaphragm during extensive surgery for pleural mesothelioma. However, new biomaterials have shown promising results in various surgical fields. This study describes our experience using homologous fascia lata for diaphragm reconstruction in patients undergoing surgery with radical intent for pleural mesothelioma. Data from patients who underwent extensive surgery for pleural mesothelioma requiring diaphragm reconstruction from January 2021 to December 2023 were extracted and analyzed. Patients were divided in two groups based on the type of material used for diaphragm reconstruction: expanded polytetrafluoroethylene (ePTFE) and cadaveric homologous fascia lata. Forty-three consecutive patients were included in the analysis. Of these, 22 patients (51 %) underwent diaphragm reconstruction with expanded ePTFE prostheses, while 21 patients (49 %) had reconstruction using homologous fascia lata. No significant differences were found between the two groups in terms of in-hospital stay (14.5 vs 17 days, p = 0.865) and early post-operative complications (19 % vs 18 %, p = 0.943). Concerning long-term complications, a lower rate was found in the group treated with fascia lata (5 % vs 23 %, p = 0.09). Diaphragm reconstruction using cadaveric homologous fascia lata after extended surgery for pleural mesothelioma is feasible and results in satisfactory post-operative outcomes. Although the trend suggests fewer long-term complications with fascia lata, further research is needed to confirm these findings and determine the ideal prosthetic material for diaphragm reconstruction.

25 September 2026 in Updates in Surgery
Verified
Journal Article
Open access
PDF file
GZGiovanni Zambello
Giovanni Zambello
ABAlberto Busetto
Alberto Busetto
RARiccardo Amatucci
Riccardo Amatucci
MPMarco Damiano Pipitone
Marco Damiano Pipitone
GCGiovanni Coppi
Giovanni Coppi
FZFrancesco Zaraca
Francesco Zaraca
Advanced non-small cell lung cancer (NSCLC) with thoracic aortic invasion (T4Ao) is a life-threatening condition and represents a major therapeutic challenge. Radiotherapy (RT) is often recommended for local control or palliation; however, it carries a substantial risk of vascular complications, including aortic rupture, thrombosis and pseudoaneurysm formation. Thoracic endovascular aortic repair (TEVAR) provides mechanical reinforcement of the aortic wall, potentially mitigating these risks and enabling safer administration of high-dose RT. This technical note describes our experience with prophylactic TEVAR (p-TEVAR) performed prior to RT. Three patients with cT4Ao-NSCLC completed the procedure and subsequent treatment without procedure-related vascular complications, achieving partial tumor response in two patients. Follow-up ranged from 6 to 10 months after radiotherapy, with no evidence of endoleak, graft migration, thrombosis, pseudoaneurysm, or aortic rupture. p-TEVAR may represent a feasible adjunct to radiotherapy or chemoradiotherapy in selected patients with advanced thoracic malignancies involving the aorta. This study highlights the feasibility of endovascular reinforcement and the importance of multidisciplinary decision-making.

Verified
Journal Article
Open access
PDF file
GZGiovanni Zambello
Giovanni Zambello
ABAlessandro Bonis
Alessandro Bonis
RARiccardo Amatucci
Riccardo Amatucci
BFBirgit Feil
Birgit Feil
LMLuiz Felippe Milazzo
Luiz Felippe Milazzo
FZFrancesco Zaraca
Francesco Zaraca
Background: Blunt thoracic aortic injury (BTAI) is an uncommon but life-threatening consequence of blunt thoracic trauma. Left-sided hemothorax is frequently identified during initial evaluation and typically prompts early chest drainage. However, when an unrecognized BTAI is present, pleural decompression may precipitate hemodynamic instability. This study aimed to identify early predictors of BTAI requiring thoracic endovascular aortic repair (TEVAR) in patients presenting with left-sided hemothorax. Methods: We conducted a single-center retrospective cohort study including consecutive trauma patients aged ≥ 16 years with radiologically confirmed left-sided hemothorax between 2015 and 2025. Patients were stratified according to the need for TEVAR. Clinical, laboratory, and radiological variables available at emergency department admission were analyzed. Independent predictors of BTAI requiring TEVAR were identified using multivariable logistic regression. Results: Among 146 included patients, 27 (18%) underwent TEVAR for confirmed BTAI. Patients requiring TEVAR were generally younger and more frequently involved in high-energy trauma. Independent predictors of TEVAR included high-energy mechanism (p = 0.048), lower admission hemoglobin (p = 0.007), presence of extra-thoracic fractures (p < 0.001), and a higher number of right-sided rib fractures (p = 0.018). The volume of left-sided hemothorax was not independently associated with BTAI. The model demonstrated strong discriminative ability (AUC = 0.926). Conclusions: In trauma patients with left-sided hemothorax, BTAI requiring TEVAR may occur even in the presence of minimal pleural effusion. Readily available admission parameters may help identify patients who could benefit from a CT angiography-first approach rather than routine early chest drainage, except in cases of immediate life-threatening pleural compromise.

16 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
DDDomenico Damiani
Domenico Damiani
IGIlaria Girolami
Ilaria Girolami
EHEsther Hanspeter
Esther Hanspeter
CMChristine Mian
Christine Mian
CSChristine Schwienbacher
Christine Schwienbacher
Georgia LevidouGeorgia Levidou
Georgia Levidou
Background: Malignant pleural effusion (MPE) represents a frequent and clinically challenging manifestation of advanced malignancy, particularly in metastatic non-small cell lung cancer (NSCLC). Its management requires integration of diagnostic imaging, symptom-directed therapeutic strategies, and, increasingly, molecular profiling technologies. Recent advancements in this field based on liquid medium (so-called liquid biopsy) have achieved a significant increase in sensitivity, enhancing our ability to investigate biofluids and suggesting their potential integration into standard diagnostic practices, far beyond the canonical plasma biopsies. Fluid obtained from MPE after cytological sample centrifugation is rich in cell-free DNA and less susceptible to nucleic acid degradation during processing, improving overall diagnostic accuracy. Methods: This narrative review summarizes current evidence on the clinical management of malignant pleural effusions in patients with metastatic NSCLC, integrating imaging, procedural management, and molecular profiling from a multidisciplinary tumor board perspective. The primary objective was to synthesize contemporary knowledge with particular attention to the feasibility, reliability, and reproducibility of pleural fluid-based molecular testing. Results: MPE poses diagnostic and therapeutic challenges for all members of the multidisciplinary tumor board, traditionally associated with an adverse prognosis. However, recent advances in cytopathology, histopathology, and liquid-based techniques demonstrate that MPE could be an important source of prognostic or predictive information. At the same time, optimal patient management requires careful integration of imaging findings and procedural strategies (such as pleurodesis or indwelling pleural catheters) with individualized systemic therapy selection. Cell-free DNA in pleural effusions is a promising field of exploration and study, potentially suitable for future guideline implementation, after validation in adequately powered studies, contributing to improving patient management, particularly useful in fragile subsets. Conclusions: The management of MPE in advanced NSCLC is evolving toward a multidisciplinary, precision-oriented model that integrates clinical evaluation, imaging, procedural interventions, and molecular testing. Liquid biopsy technology has gained enough analytical robustness and clinical feasibility to be a useful tool in routine analysis. Biofluid-based molecular testing may have outstanding potential, contributing to improving patient management, avoiding repetitive procedures, and optimizing the overall efficiency and cost-effectiveness of diagnostic practices. Moreover, collaborative projects among different specialties help in consolidating trust in the tumor board decision-making process.

2 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GCGiovanni Coppi
Giovanni Coppi
LMLuiz Felippe Milazzo
Luiz Felippe Milazzo
MPMarco Damiano Pipitone
Marco Damiano Pipitone
GZGiovanni Zambello
Giovanni Zambello
FZFrancesco Zaraca
Francesco Zaraca
PPPerkmann Perkmann
Perkmann Perkmann
Background: Current guidelines recommend delaying extracranial carotid revascularization for at least 6–7 days after intravenous thrombolysis (IVT). However, evidence remains inconclusive, and patients with minimal or no brain lesions may benefit from earlier intervention. Objective: This scoping review evaluates outcomes of carotid revascularization performed within six days of IVT in patients with small strokes or no imaging-detected lesions. Design: We searched Medline, EMBASE, and Cochrane CENTRAL for studies published between 2005 and 2025 reporting carotid revascularization after IVT. Primary outcomes included perioperative ischemic stroke, symptomatic intracranial hemorrhage (sICH), asymptomatic intracranial bleeding (aICB), and wound complications. Data on timing, imaging findings (CT/MRI), and stroke severity (NIHSS or modified Rankin scale) were extracted. The review followed PRISMA-ScR guidelines. Results: Seventeen studies (1459 patients) were included; 97.6% underwent carotid endarterectomy (CEA) and 2.4% carotid artery stenting (CAS). Data for procedures within six days post-IVT were available for 402 patients, with some treated within 24–72 h. Mean NIHSS at admission was 10.2 ± 2.8. Brain lesion characterization was poor and only used as an exclusion criterion. Thirty-day ischemic stroke incidence was 2.5%, while combined sICH/aICB was 4.0%, with symptomatic cases at 2.5%. Most hemorrhages occurred in patients operated within 48–72 h from IVT and in patients with higher NIHSS. CAS carried higher sICH risk than CEA (8.6% vs. 1.9%). Overall mortality was 1.1%; wound complications occurred in 3.7%. Conclusions: The available literature provides limited characterization of brain lesion extent. Neurological complications after CEA are rare, mainly limited to patients operated within 48–72 h from IVT. Further research is needed to optimize treatment in this patient group, although delaying CEA only to 48–72 h seems reasonable in case of low NIHSS.